Efficacy of dual therapy in patients >65 years old with alanine transaminase flare during chronic hepatitis C genotype 2

  • Elena Garlatti Costa | elenagarlatti@yahoo.it UO Internal Medicine 2, Department of Internal Medicine, AO Santa Maria degli Angeli, Pordenone, Italy.
  • Michela Ghersetti UO Internal Medicine 2, Department of Internal Medicine, AO Santa Maria degli Angeli, Pordenone, Italy.
  • Silvia Grazioli UO Internal Medicine 2, Department of Internal Medicine, AO Santa Maria degli Angeli, Pordenone, Italy.
  • Pietro Casarin UO Internal Medicine 2, Department of Internal Medicine, AO Santa Maria degli Angeli, Pordenone, Italy.

Abstract

Hepatitis C virus (HCV)-related chronic hepatitis is characterized by different clinical outcomes as well as by distinct biochemical and virological patterns. According to guidelines concerning dual therapy, high rates of sustained virological response (or HCV-RNA undetectable 24 weeks after the end of antiviral treatment) has been obtained in patients with persistent HCV infection, caused by genotype 2 (CHC G2). Dual therapy (pegylated interferon plus ribavirin) might be an useful strategy not only in the treatment of younger patients (≤65 years old, that is generally considered as age limit for the beginning of the antiviral treatment) but also of older patients (>65 years old) experiencing an alanine aminotransferase (ALT) flare (with value of ALT-alanine transaminase ≥400 U/L). In fact the progress of fibrosis can advance quicker exactly during the transaminase breakthrough. We report our experience in the treatment of two Italian patients with CHC G2, one of them was a never treated (naive) woman, whereas the other was a previously treated man with several co-morbidities. Both patients presented an excellent virological response to dual therapy despite unfavorable predictive factors, such as old age (>65 years), ALT flare and possible moderate hepatic fibrosis.

Downloads

Download data is not yet available.
Published
2015-03-20
Section
Case Reports
Keywords:
hepatitis C virus, chronic hepatitis C genotype 2, alanine aminotransferase, persistent normal alaninoamino transferase, dual therapy, rapid virological response, sustained virological response.
Statistics
Abstract views: 739

PDF: 435
HTML: 266
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Garlatti Costa, E., Ghersetti, M., Grazioli, S., & Casarin, P. (2015). Efficacy of dual therapy in patients >65 years old with alanine transaminase flare during chronic hepatitis C genotype 2. Italian Journal of Medicine, 9(1), 82-88. https://doi.org/10.4081/itjm.2015.471